|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together our data suggest that these small molecules may hold potential as effective therapeutic agents for the treatment of neuroblastoma and other MYC-driven cancers.
|
24282277 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of c-myc and N-myc genes by dsRNAs in carcinoma and neuroblastoma cells was investigated. siRNA-Ex3 targeted to the third exon of c-myc gene was found to decrease the level of c-myc but not N-myc mRNA and decrease the rate or even arrest proliferation of c-myc overexpressing cell lines KB-3-1 and SK-N-MC.
|
17341633 |
2006 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
|
27197232 |
2016 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that MYCN/MYC-mediated overactivation of the metaphase-anaphase checkpoint synergizes with loss of p53-p21 function to prevent arrest or apoptosis of tetraploid neuroblastoma cells.
|
23186832 |
2013 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
TFs like MYC and PTEN having six types of adjacent nodes and other classes of TFs investigated really can help to demonstrate that TFs affect pathways through expressions of significant miRNAs involved in the pathogenesis of NB.
|
25292042 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.
|
23153536 |
2012 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox.
|
28684529 |
2017 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
|
31406244 |
2019 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In MYC-amplified neuroblastoma patient samples, there was a significant correlation between SHMT2 and hypoxia-inducible factor-1 α (HIF1α), and SHMT2 expression correlated with unfavorable patient prognosis.
|
25186948 |
2014 |
|
Neuroblastoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our finding that MYCN directly modulates baseline MDM2 levels suggests a mechanism contributing to the pathogenesis of neuroblastoma and other MYC-driven malignancies through inhibition of MYC-stimulated apoptosis.
|
15644444 |
2005 |
|
Neuroblastoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
MYC has been shown to associate with DNA methyltransferases, thereby inducing transcriptional repression of target genes, which suggested that MYCN might play a similar mechanistic role in the hypermethylation of tumor suppressor genes in neuroblastoma.
|
23280764 |
2014 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
It was found that Hsp90 inhibition in neuroblastoma cell lines resulted in significant growth suppression, a decrease in MYCN and MYC expression, and an increase in the expression of p53.
|
21109931 |
2011 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We identified a genetic signature characterized by a subset of MYCN/MYC and E2F targets, including Skp2, encoding the F-box protein of the SCF(Skp2) E3-ligase, to be highly expressed in high-risk neuroblastomas independent of amplified MYCN.
|
17652624 |
2007 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
An element in the region responsible for premature termination of transcription mediates repression of c-myc gene expression by thyroid hormone in neuroblastoma cells.
|
10625678 |
2000 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Specific inhibition of hyperactive rRNA synthesis and protein translation was shown to be an effective way to suppress MYC/MYCN protein expression and neuroblastoma growth.
|
29464082 |
2018 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Analysis of human neuroblastoma tumor specimens revealed that MYC up-regulation correlates with markers of TAM infiltration.
|
29207662 |
2017 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Relationship between bcl-2 and myc gene expression in human neuroblastoma.
|
7767905 |
1995 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis.
|
26373717 |
2016 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we found miR-1303 was upregulated in NB cells and tissues, miR-1303 overexpression promoted the proliferation of SH-SY5Y NB cell investigated by MTT assay, colony formation assay and anchorage-independent growth ability assay, while miR-1303 knockdown reduced this effect. mechanism analysis suggested glycogen synthase kinase 3 beta (GSK3β) and secreted frizzled-related protein 1 (SFRP1) were the target of miR-1303, luciferase assay revealed miR-1303 directly bound to the 3'UTR of GSK3β and SFRP1. miR-1303 increased expression of MYC and CyclinD1, and decreased the expression of p21 and p27, and further demonstrated miR-1303 promotes NB proliferation.
|
27434867 |
2016 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although MYC translocations define Burkitt lymphoma and MYC protein expression is a poor prognostic factor in undifferentiated neuroblastomas, the distribution of MYC protein (c-MYC) across other pediatric small round blue cell tumors (SRBCT) has not been well characterized.
|
28521631 |
2017 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The xenografts established from the NB iCSCs shared two common features: the LCN phenotype and high-level MYC/MYCN expression.
|
23479628 |
2013 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Clinical data set analysis of MYCN, MYC and TWIST1 expression permits us to confirm that TWIST1 expression is upregulated in MYCN amplified neuroblastoma but also in a subset of neuroblastoma harboring high expression of MYCN or MYC without gene amplification.
|
25475555 |
2015 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The N-myc gene, first detected by its homology to the second exon of the c-myc gene, is amplified and/or expressed in tumours or cell lines derived from neuroblastoma, retinoblastoma and SCLC.
|
2997622 |
1985 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In sharp contrast to MYCN, enforced expression of c-MYC did not enhance OCT4 expression in human neuroblastoma cells.
|
25880909 |
2015 |
|
Neuroblastoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification or overexpression of neuronal MYC (MYCN) is associated with poor prognosis of human neuroblastoma.
|
26156430 |
2015 |